Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
PF-03654764 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| PF-03654764 + Allegra | EXPERIMENTAL | - |
| PF-03654764 | EXPERIMENTAL | - |
| Allegra-D | ACTIVE_COMPARATOR | - |
| Placebo | PLACEBO_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| PF-03654764 | DRUG | PF-03654764 single dose 5 mg |
| Allegra | DRUG | Fexofenadine single dose 60 mg |
| Allegra-D | DRUG | Fexofenadine 60 mg combined with pseudoephedrine 120 mg single dose |
| Placebo | DRUG | Placebo single dose |
Inclusion Criteria: * Male or female subjects 18-60 years allergic to ragweed pollen. * Subjects with appropriate symptom scores following exposure to ragweed in the environmental exposure unit. Exclusion Criteria: * Subjects with significant diseases other than allergic rhinitis that may interfe...
Top 1 of 3 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Eli Lilly and Company | LLY | 1 | PHASE3 | LY3650150 |
PF-03654764 was developed for the treatment of allergic rhinitis. It is an investigational small molecule studied by Pfizer as a potential therapy for nasal allergy symptoms, including in combination with the antihistamine Allegra (fexofenadine). It has not been approved for any indication.
PF-03654764 targets HRH3, the histamine H3 receptor, acting as an antagonist. By blocking this receptor, the drug was designed to modulate histamine signaling relevant to allergic rhinitis symptoms. HRH3 antagonism was the intended mechanism explored in its clinical program.
PF-03654764 is developed by Pfizer, Inc., which trades on the New York Stock Exchange under the ticker PFE. Pfizer sponsored the clinical research evaluating the compound in allergic rhinitis.
PF-03654764 reached Phase 2 clinical development for allergic rhinitis. It is an investigational drug and has not been approved by the FDA. Its single recorded Phase 2 trial has been completed, and no active trials are currently listed.
PF-03654764 was evaluated in one Phase 2 trial, NCT01033396, titled "The Effect Of PF-03654764 +/- Allegra On Symptoms Of Allergic Rhinitis." The completed trial enrolled 64 participants in Canada, was randomized, double-blind, and placebo-controlled, and included adults 18 years and older.